- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Eikon Therapeutics, Inc.: Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald | 2 | GlobeNewswire (USA) | ||
| 13.08. | Eikon Therapeutics, Inc. GAAP EPS of -$1.63 misses by $0.03 | 1 | Seeking Alpha | ||
| 13.08. | Eikon Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates | 158 | GlobeNewswire (Europe) | Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon's oncology portfolio, including clinical... ► Artikel lesen | |
| 11.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma | 395 | GlobeNewswire (Europe) | Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee... ► Artikel lesen | |
| 10.08. | Eikon Therapeutics adds Merck chemistry head to advisory board | 3 | Investing.com | ||
| EIKON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.08. | Merck Chemiechef verstärkt wissenschaftlichen Beirat von Eikon Therapeutics | 4 | Investing.com Deutsch | ||
| 10.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board | 396 | GlobeNewswire (Europe) | MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 03.08. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | Eikon Therapeutics doses first patient in lung cancer trial | 1 | Investing.com | ||
| 27.07. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer | 164 | GlobeNewswire (Europe) | MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to... ► Artikel lesen | |
| 20.07. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress | 1 | GlobeNewswire (USA) | ||
| 25.06. | Eikon Therapeutics to join Russell 3000 index | 1 | Seeking Alpha | ||
| 25.06. | Eikon Therapeutics, Inc.: Eikon Therapeutics to Join the Russell 3000 Index | 144 | GlobeNewswire (Europe) | MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 10.06. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Eikon Therapeutics beruft Ma. Fatima Francisco in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 08.06. | Eikon Therapeutics appoints Francisco to board of directors | 1 | Investing.com | ||
| 02.06. | Cantor Fitzgerald reiterates Overweight on Eikon stock | 1 | Investing.com | ||
| 01.06. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Eikon Therapeutics, Inc.: Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,474 | +7,58 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,600 | -6,47 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,582 | -4,35 % | Cardiol Therapeutics GAAP EPS of -C$0.05 | ||
| CELLECTAR BIOSCIENCES | 2,520 | -3,82 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CYTODYN | 0,170 | +1,19 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,763 | -0,91 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,192 | 0,00 % | Wettbewerbsdruck bei Naloxon: S&P stuft Ausblick für Emergent BioSolutions auf negativ herab | ||
| DENALI THERAPEUTICS | 21,320 | -3,09 % | DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? | ||
| CEL-SCI | 1,290 | +2,38 % | CEL-SCI Signs Saudi Arabia Multikine Commercialization Deal With 50/50 Net Revenue Split | ||
| COHERUS ONCOLOGY | 1,188 | +5,51 % | Coherus Oncology, Inc.: Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | - Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets - - Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company... ► Artikel lesen | |
| CURIS | 1,622 | +11,37 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,948 | -3,44 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,100 | -7,65 % | Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated... ► Artikel lesen | |
| FAETH THERAPEUTICS | 26,800 | -7,59 % | XFRA 4070: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYBIN | 10,580 | +4,96 % | Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board | Former Intra-Cellular Therapies, Inc. ("Intra-Cellular") executives bring complementary experience in organizational scale-up, central nervous system ("CNS") drug development, regulatory approvals... ► Artikel lesen |
EIKON THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -10,59 % bei einem Aktienkurs von 10,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EIKON THERAPEUTICS INC finden Sie auf Wallstreet Online.